Jennifer Patritti Cram, Ph.D., is a registered patent agent who centers her practice on patent prosecution related to life sciences, biotechnology, and pharmaceutical matters. Her practice encompasses a broad range of subjects including cancer immunotherapies, antibody-based therapeutics, cellular therapies, pharmaceuticals, immunology, virology, DNA-based drugs, sequencing (genomics SNPs, gene expression), and medical devices. Jennifer has experience assisting clients in drafting and prosecuting patent applications, researching and analyzing prior art, and performing freedom-to-operate analysis and patent portfolio management (including US and non-US patent prosecution).
Before joining Morgan Lewis, Jennifer completed her Ph.D. in neurosciences, during which time she made novel discoveries on the signaling mechanism of peripheral nerve tumor formation in neurofibromatosis type 1 (NF1) using in vitro cell culture models and in vivo mouse models. Jennifer’s doctoral research led to the publication of numerous peer-reviewed journal articles, including P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis, Elife. 2022 Mar 21;11:e73511; and Purinergic Signaling in Peripheral Nervous System Glial Cells, Glia. 2021 Aug;69(8):1837-1851. Her research findings have also been presented at scientific conferences, both nationally and internationally.
Young Investigator Award, Children’s Tumor Foundation (2020–2022)
Ruth L. Kirschstein Institutional National Research Service Award in the Neurosciences, T-32, National Institute of Health (2016–2018)
Albert C. Yates Fellowship, Graduate School of the University of Cincinnati (2016–2021)
Fellow at Yale Ciencia Academy for Career Development Program (2017–2018)
Graduate Dean’s Excellence Scholarship, University of Cincinnati (2016)
Pelotonia Fellowship for Cancer Research, The James Comprehensive Cancer Research Center, The Ohio State University (2015–2016)